Skip to content
MarketScale
‹ Back to IndustriesSciences

How NASA Used Automation to Bring InSight Lander to Mars

On Nov. 26, NASA successfully grounded the InSight Lander on the plains of Elysium Planitia on Mars. The goal is to study the interior of Mars, including its crust, mantle, and core as well as to understand the formation and evolution of Mars. The mission will also seek to discover tectonic activity and meteorite activity…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin ·
Share
How NASA Used Automation to Bring InSight Lander to Mars

Key takeaways

01

26, NASA successfully grounded the InSight Lander on the plains of Elysium Planitia on Mars.

02

The goal is to study the interior of Mars, including its crust, mantle, and core as well as to understand the formation and evolution of Mars.

03

The mission will also seek to discover tectonic activity and meteorite activity…

On Nov. 26, NASA successfully grounded the InSight Lander on the plains of Elysium Planitia on Mars. The goal is to study the interior of Mars, including its crust, mantle, and core as well as to understand the formation and evolution of Mars. The mission will also seek to discover tectonic activity and meteorite activity rate on the planet. The lander is designed to provide data for almost two Earth years (one Martian year).

The Mars lander is powered using solar power. After the dust settled from the landing, the solar array deployed and unfolded. It is also equipped with a robotic arm whose job it is to both deploy the scientific instrumentation and to provide 3D photographs of the landing area. The instruments are very sensitive and must be deployed carefully. This is the first time a robotic arm has been used to do this. The instruments being deployed have been built in the U.S., Germany, and France, showing the degree to which this is a truly international project.

Given NASA’s goal of sending human beings to Mars in the near future, meaning there will have to be facilities already there for the astronauts to work and live in, this data has more than just pure scientific value. The more that is understood about the planet, both inside and out, the more likely a manned trip to Mars will be.

Printing our way to Martian facilities

If you are wondering how it is that there can be facilities on Mars waiting for astronauts, when surely one would need someone there to build the facilities, NASA already has a solution: 3D printing. After running a contest to find the best 3D printing solution to create a Martian habitat, NASA has recently declared five winning entries.

Of course, NASA is hardly the only institution trying to put people on Mars. In the private sector, Elon Musk’s Space X is also actively trying to create the conditions for a successful trip to Mars that is designed to result in the establishment of a successful Mars colony. This means the company will need to develop the kind of infrastructure necessary to make such a colony succeed. Most likely it will have to rely on 3D printing for initial infrastructure so it will be ready for use when people arrive. This process will have to be automated.

On Mars as it is on Earth

Much of the infrastructure that would have to be built would be Martian equivalents to what we have here on Earth. Much of this construction equipment will have to be light, small, and automatic. It will have to fit on rockets and because radio waves can take between four and 24 minutes to reach Mars from Earth, any machines will need to be as fully autonomous as possible.

These preparations for Mars will not only help us to live on Mars, but will also benefit us here on Earth. Three-dimensional printers to build structures, fully autonomous machines, and smaller, lighter equipment are all critical to the future of Earth but also the establishment of viable and sustainable operations on the red planet. So, if you’re excited about technological innovations that will help us here on Earth, you should be very excited about our plans for a future on Mars.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

TC
Troy Camplin

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512